A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of treatment with Xeloda plus
standard pelvic radiotherapy in participants with locally advanced rectal cancer. Eligible
participants will receive Xeloda 825mg/m^2 orally twice daily plus standard radiotherapy for
5 weeks, followed by surgery within 6 weeks after completion of treatment. The anticipated
time on study treatment is < 3 months, and the target sample size is < 100 individuals.